Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT05119179
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT05119179
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05119179. Allocation not applicable; no masking; primary purpose treatment. Start 2021-11-22 (actual); primary completion 2026-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
- Condition
- PreDiabetes
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Collaborator
- Vanderbilt University Medical Center
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct05119179- Content hash
440dd68db77d9e4a77b674f31a75c52731e95ecc56244e50414685c7ec85d1ea